Vertex PharmaceuticalsVRTXRevenue: is the business selling more than it used to?
$12.0B+9% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Revenue reached $12.0B in 2025, compounding +10% a year since 2022 though the pace has cooled. The trailing twelve months are already running at $12.6B, ahead of the last full year.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Vertex PharmaceuticalsVRTXNet income: how much of that revenue becomes profit?
$4.0BFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Net income was $4.0B in 2025, compounding +6% a year over three years. Trailing twelve-month profit stands at $4.4B.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Vertex PharmaceuticalsVRTXHow fast is it growing, year by year?
+8.9%revenue growth, FY 2025
Off the axis: 2012 earnings -461.9% · 2018 earnings +695.8% - rebounds off a collapsed prior year.
→Revenue grew +9% in 2025 against a five-year average of +14%. 2012's swing into loss (-462%) and 2018's +696% earnings rebound off a collapsed base sits off the axis.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Vertex PharmaceuticalsVRTXRevenue per share: is your slice growing as fast as the company?
$46.52revenue per share, FY 2025
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→Revenue per share reached $46.52 in 2025, compounding +11% a year - in line with VRTX's own +10%, so the share count is not distorting your slice. Free cash flow per share stands at $12.38.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Vertex PharmaceuticalsVRTXFree cash flow: what is left in real cash after everything?
$3.2BFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Free cash flow was $3.2B in 2025, compounding -7% a year since 2022. The trailing twelve months stand at $3.8B.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Vertex PharmaceuticalsVRTXHow much of every sales dollar ends up as free cash?
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→27 cents of every sales dollar became free cash in 2025, down 17 points since 2022.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Vertex PharmaceuticalsVRTXWhat does staying competitive cost, per dollar of sales?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→The biggest claim on each sales dollar is research and development, at 40% of revenue (stock compensation 6%, capital spending 4%).
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Vertex PharmaceuticalsVRTXWhen sales grow, do profits grow faster?
→Operating profit outgrew revenue in only 2 of the last 5 years. Costs are growing roughly in step with the business, so scale isn't yet paying for itself.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Vertex PharmaceuticalsVRTXMargins: of every $1 of sales, how much survives each cost layer?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→Operating margin compressed 13 points to 35% since 2022. After everything, 33 cents of each sales dollar reaches net profit. VRTX doesn't tag a gross-profit line in its filings, so the chart starts at operating margin.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Vertex PharmaceuticalsVRTXWhat does it earn on the money it uses?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→ROE of 22% and ROCE of 19% sit close together, so the returns come from the business itself rather than from borrowing.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Vertex PharmaceuticalsVRTXWhat has the market paid for VRTX over time?
32.0xP/E today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→At 32.0x earnings, the market is paying +31% more than VRTX's own 8-year median of 24.4x. Expectations are elevated, so more has to go right to justify the price.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Vertex PharmaceuticalsVRTXWhat cash return does the business throw off per dollar of market value?
2.7%FCF yield today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→Every dollar of market value currently buys 2.7% of annual free cash flow, right at VRTX's 11-year median of 2.8%.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Vertex PharmaceuticalsVRTXCould it handle its debt if things went wrong?
→Debt isn't clearly tagged in VRTX's filings, so treat the balance sheet with extra care rather than assuming zero.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Vertex PharmaceuticalsVRTXIs the company's own capital growing?
→The company's own capital grew from $17.6B in 2023 to $20.2B (+15%). The business is building book value rather than consuming it.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Vertex PharmaceuticalsVRTXHow much goes back, and how much leaks out as stock comp?
→Shareholders received $2.0B in buybacks in 2025. Stock compensation issued $686M of new shares in the same year, offsetting 34% of that.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Vertex PharmaceuticalsVRTXHow fast is your ownership being diluted - or concentrated?
→The share count grew 0.0% in 2025. Your slice of the company shrinks by that much each year unless earnings grow faster.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Vertex PharmaceuticalsVRTXDoes VRTX earn more on its capital than that capital costs?
→VRTX earns 19.2% on the capital it employs, comfortably above the 10% most investors treat as the cost of capital. It was 28.0% in 2022, so the trend is down, though the pace has cooled.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Vertex PharmaceuticalsVRTXVRTX has issued or retired shares - did shareholders end up better off?
→VRTX issued +24% more shares from 2011 to 2025, but revenue per share still rose +589%. The dilution bought more growth than it cost existing holders.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Vertex PharmaceuticalsVRTXAre the people running it buying or selling?
→Insiders sold $38M on the open market and bought nothing. Many sales are pre-scheduled diversification rather than a view on the price. A further 13 filings were grants, option exercises or tax withholding, which say nothing either way.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30